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INTRODUCTION 
 
Tuberculosis caused by Mycobacterium Tuberculosis remain a major health 
issue worldwide , roughly one third of worlds population has been infected with   
Mycobacterium Tuberculosis with new infections occurring in about 1% of the 
population each year An estimated 1o.4 million people fell ill with TB in 2o16: 
9o% were adults, 65% were male . Tuberculosis is the second most common cause 
of death from infectious diseases, India had the largest total incidence with an 
estimated 2.0 million new cases. Cardiovascular   involvement occurs in one to 
two percent of the patients with pulmonary tuberculosis and usually affects the 
pericardium and myocardium rarely valves are involved, very less work has been 
done to determine cardiac manifestations in pulmonary tuberculosis. The objective 
was to study the electrocardiographic changes in sputum positive pulmonary 
tuberculosis patients before and after anti-tuberculosis treatment with six months 
follow up to know the influence of anti- tuberculosis treatment over 
electrocardiographic changes and cardiac manifestations in pulmonary tuberculosis 
patients. 
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AIM OF THE STUDY 
 
1) To study the electrocardiographic changes in untreated cases of sputum 
positive pulmonary tuberculosis. 
 
2) To follow up for six months and study whether the electrocardiographic 
changes are markedly decreased or normalized after anti-tuberculosis 
therapy 
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REVIEW OF LITERATURE 
 
Tuberculosis is caused by Mycobacterium tuberculosis. Its remains a 
worldwide health problem inspite of the fact that organism was discovered 1oo 
years back.  Tuberculosis affects primarily the lungs but it can affect also intestine, 
meninges, bones, joints, lymphnodes, skin .Sometimes it affects animals called 
BOVINE tuberculosis. The tubercle bacilli was discovered by ROBERT KOCH in 
1882 The disease was called “CONSUMPTION” in the past because of the way it 
would consume from within anyone who became infected .It can affect any age 
group. In 1993 WHO declared TB as global health problem About 1/3 of 
population was infected with tuberculosis bacilli, Most maternal deaths occurred 
due to tuberculosis. The burden of tuberculosis was more from Asia and Africa. 
TB is the ninth leading cause of death worldwide and the leading cause from a 
single infectious agent, ranking above HIV/AIDS. In 2o16, there were an 
estimated 1.3 million TB deaths among HIV-negative people (down from 1.7 
million in 2000) and an additional 374000 deaths among HIV-positive people. An 
estimated 1o.4 million people fell ill with TB in 2o16: 9o% were adults, 65% were 
male, 1o% were people living with HIV (74% in Africa) and 56% were in five 
countries: India, Indonesia, China, the Philippines and Pakistan. Drug-resistant TB 
is a continuing threat. In 2016, there were 600000 new cases with resistance to 
rifampicin (RRTB), the most effective first-line drug, of which 490 000 had 
multidrug-resistant TB (MDR-TB). Almost half (47%) of these cases were in 
India, China and the Russian Federation. Globally, the TB mortality rate is falling 
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at about 3% per year. TB incidence is falling at about 2% per year and 16% of TB 
cases die from the disease; by 2o2o, these figures need to improve to 4–5% per 
year and 1o%, respectively, to reach the first (2o2o) milestones of the End TB 
Strategy. Most deaths from TB could be prevented with early diagnosis and 
appropriate treatment. Millions of people are diagnosed and successfully treated 
for TB each year, averting millions of deaths (53 million 2ooo–2o16), but there are 
still large gaps in detection and treatment. In 2o16, 6.3 million new cases of TB 
were reported (up from 6.1 million in 2o15), equivalent to 61% of the estimated 
incidence of 1o.4 million; the latest treatment outcome data show a global 
treatment success rate of 83%, similar to recent years. There were 476 774 
reported cases of HIV-positive TB (46% of the estimated incidence), of whom 
85% were on antiretroviral therapy (ART). A total of 129 689 people were started 
on treatment for drug-resistant TB, a small increase from 125 629 in 2o15 but only 
22% of the estimated incidence THE NATIONAL TUBERCULOSIS 
PROGRAME was started on 1997 was not able to achieve high cure rates in 
developing countries  .Reasons are poverty, economic recession, malnutrition, 
family problems, overcrowding, Tobacco, alcohol abuse, air pollution, diabetes. 
To make situation worse tuberculosis and HIV lethal combination, one making the 
other worse. 
 
Epidemiological indices: 
Presumptive case: Refers to patient who present with sign and symptom 
suggestive of tuberculosis 
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Case definition: a bacteriologically confirmed TB case is one from whom a 
biological specimen is positive by smear microscopy, culture, A clinically 
diagnosed tb who does not fulfil the criteria for bacteriological confirmation but 
has been diagnosed by physician who has decided to give a full course of TB 
treatment. 
 
Treatment completed: 
A TB patient who completed treatment without evidence of failure BUT 
with no record to show that sputum smear or culture results in the last month of 
treatment and on at least one previous occasion were negative, either because tests 
were not done or because results are unavailable. 
 
Treatment failed: A TB patient whose sputum smear or culture is positive at 
month 5 or later during treatment. 
 
Died: TB patient who dies for any reason before starting or during the course of 
treatment. 
 
Lost to follow-up: A TB patient who did not start treatment or whose treatment 
was interrupted for 2 consecutive months or more. 
 
Not evaluated : A TB patient for whom no treatment outcome is assigned. This 
includes cases "transferred out" to another treatment unit as well as cases for 
whom he treatment outcome is unknown to the reporting unit. 
 
Treatment success: The sum of cured and treatment completed . 
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Classification based on history of previous TB treatment: 
Classifications based on history of previous TB treatment are slightly different 
from those previously defined. They focus only on history of previous treatment 
and are Independent of bacteriological confirmation or site of disease. 
 
New patients: Patients who have never been treated for TB or have taken anti-TB 
drugs for less than 1 month. 
 
Previously treated patients: Patients who received 1 month or more of anti-TB 
drugs in the past. 
They are further classified by the outcome of their most recent course of treatment 
as follows: 
1) Relapse patients have previously been treated for TB, were declared cured 
or treatment completed at the end of their most recent course of treatment, 
and are now diagnosed with a recurrent episode of TB (either a true relapse 
or a new episode of TB caused by reinfection). 
2) Treatment after failure patients are those who have previously been treated 
for TB and whose treatment failed at the end of their  most recent course of 
treatment. 
3) Treatment after loss to follow-up patients have previously been treated for 
TB and were declared lost to follow up at the end of their most recent 
course of treatment. (These were previously known as treatment after 
default patients.) 
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4) Other previously treated patients are those who have previously been 
treated for TB but whose outcome after their most recent course of 
treatment is unknown or undocumented. 
5) Patients with unknown previous· TB treatment history do not fit into any of 
the categories listed above.   
 
Classification based on drug resistance 
a. Monoresistance: resistance to one first-line anti-TB drug only. 
b. Polydrug resistance: resistance to more than one first line anti-TB drug (other 
than both isoniazid and rifampicin). 
c. Multidrug resistance: resistance to at least both isoniazid and rifampicin. 
d. Extensive drug resistance: resistance to any fluoroquinolone and at least one 
of three second-line injectable drugs (capreomycin, kanamycin and amikacin), in 
addition to multidrug resistance. 
 
PATHOGENESIS  
The pathogenesis of tuberculosis in the previously unexposed 
immunocompetent person is entered on the development of a targeted cell-
mediated immunity that confers resistance to the organism and results in 
development of tissue hypersensitivity to tubercular antigens. The pathologic 
features of tuberculosis, such as caseating granulomas and cavitation, are the result 
of the destructive tissue hypersensitivity that is part and parcel of the host immune 
response. Because the effector cells for both processes are the same, the 
appearance of tissue hypersensitivity also signals the acquisition of immunity to 
the organism. 
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Figure - 1 
 
The sequence of events from inhalation of the infectious inoculum to 
containment of the primary focus .once a virulent strain of mycobacteria gains 
entry into the macrophage endosomes (a process mediated by several macrophage 
receptors, including the macrophage mannose receptor and complement receptors 
that recognize several components of the mycobacterial cell walls), theorganisms 
are able to inhibit normal microbicidal responses by preventing the fusion of the 
lysosomes with the phagocytic vacuole. 
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Figure - 2 
 
 
 
The prevention of phagolysosome formation allows unchecked 
mycobacterial proliferation. Thus, the earliest phase of primary tuberculosis (in the 
first 3 weeks) in the nonsensitized patient is characterized by bacillary 
proliferation within the pulmonary alveolar macrophages and air spaces, with 
resulting bacteremia and seeding of multiple sites. Despite the bacteremia, most 
persons at this stage are asymptomatic or have a mild flu-like illness. 
 
 The genetic makeup of the patient may influence the course of the disease. 
In some people with polymorphisms of the NRAMP1 (natural resistance–
associated macrophage protein 1) gene, the disease may progress from this 
point without development of an effective immune response. NRAMP1 is a 
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transmembrane ion transport protein found in endosomes and lysosomes 
that is believed to contribute to microbial killing. 
 The development of cell-mediated immunity occurs approximately 3 weeks 
after exposure. Processed mycobacterial antigens reach the draining lymph 
nodes and are presented to CD4 T cells by dendritic cells and macrophages. 
Under the influence of macrophage-secreted IL-12, CD4+ T cells of the 
TH1 subset are generated that are capable of secreting IFN-γ. 
 IFN-γ released by the CD4+ T cells of the TH1 subset is crucial in 
activating macrophages. Activated macrophages, in turn, release a variety 
of mediators and upregulate expression of genes with important 
downstream effects, including  TNF, which is responsible for recruitment of 
monocytes, which in turn undergo activation and differentiation into the 
“epithelioid histiocytes” that characterize the granulomatous response;  
expression of the inducible nitric oxide synthase (iNoS) gene, which results 
in elevated nitric oxide levels at the site of infection, with excellent 
antibacterial activity; and  generation of reactive oxygen species, which can 
have antibacterial activity. You will recall that nitric oxide is a powerful 
oxidizing agent that results in generation of reactive nitrogen intermediates 
and other free radicals capable of oxidative destruction of several 
mycobacterial constituents, from cell wall to DNA. 
 Defects in any of the steps of a TH1 response (including IL-12, IFN-γ, 
TNF, or nitric oxide production) result in poorly formed granulomas, 
absence of resistance, and disease progression. Persons with inherited 
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mutations in any component of the TH1 pathway are extremely susceptible 
to infections with mycobacteria. In summary, immunity to a tubercular 
infection is primarily mediated by TH1 cells, which stimulate macrophages 
to kill bacteria. This immune response, while largely effective, comes at the 
cost of hypersensitivity and the accompanying tissue destruction. 
Reactivation of the infection or re-exposure to the bacilli in a previously 
sensitized host results in rapid mobilization of a defensive reaction but also 
increased tissue necrosis. Just as hypersensitivity and resistance appear in 
parallel, so, too, the loss of hypersensitivity (indicated by tuberculin 
negativity in a tuberculin positive patient) may be an ominous sign that 
resistance to the organism has faded. 
 
Primary Tuberculosis 
Primary tuberculosis is the form of disease that develops in a previously 
unexposed and therefore unsensitized patient. Elderly persons and profoundly 
immunosuppressed patients may lose their sensitivity to the tubercle bacillus, so 
they may develop primary tuberculosis more than once. About 5%of those newly 
infected acquire significant disease. The major consequences of primary 
tuberculosis are that it induces hypersensitivity and increased resistance; the foci 
of scarring may harbour viable bacilli for years, perhaps for life, and thus be the 
nidus for reactivation at a later time when host defenses are compromised; and 
uncommonly, it may lead to progressive primary tuberculosis. 
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This complication occurs in patients who are immunocompromised or have 
nonspecific impairment of host defenses, as characteristic in malnourished children 
or in elderly persons. Certain racial groups, such as the Inuit, also are more prone 
to the development of progressive primary tuberculosis. The incidence of 
progressive primary tuberculosis is particularly high in HIV-positive patients with 
an advanced degree of immunosuppression (i.e., CD4+ counts below 2oo 
cells/..L). Immunosuppression results in an inability to mount a CD4+ T cell–
mediated immunologic reaction that would contain the primary focus; because 
hypersensitivity and resistance are most often concomitant factors, the lack of a 
tissue hypersensitivity reaction results in the absence of the characteristic caseating 
granulomas (nonreactive tuberculosis). 
 
MORPHOLOGY 
In countries in which bovine tuberculosis and infected milk have largely 
disappeared, primary tuberculosis almost always begins in the lungs. Typically, the 
inhaled bacilli implant in the distal air spaces of the lower part of the upper lobe or 
the upper part of the lower lobe, usually close to the pleura. As sensitization 
develops, a 1- to 1.5-cm area of gray-white inflammatory consolidation emerges, 
the Ghon focus. In most cases the center of this focus undergoes caseous necrosis. 
Tubercle bacilli, either free or within phagocytes, travel in lymph drainage to the 
regional nodes, which also often caseate. This combination of parenchymal lesion 
and nodal involvement is referred to as the Ghon complex. During the first few 
weeks, there is also lymphatic and hematogenous dissemination to other parts of 
the body. In approximately 95% of cases, development of cellmediated immunity 
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controls the infection. Hence, the Ghon complex undergoes progressive fibrosis, 
often followed by radiologically detectable calcification (Ranke complex), and 
despite seeding of other organs, no lesions develop.on histologic examination, sites 
of active involvement are marked by a characteristic granulomatous inflammatory 
reaction that forms both caseating and noncaseating granulomas, which consist of 
epithelioid histiocytes and multinucleate giant cells. 
 
Secondary Tuberculosis (Reactivation Tuberculosis) 
Secondary tuberculosis is the pattern of disease that arises in a previously 
sensitized host. It may follow shortly after primary tuberculosis, but more 
commonly it arises from reactivation of dormant primary lesions many decades 
after initial infection, particularly when host resistance is weakened. It also may 
result from exogenous reinfection because of waning of the protection afforded by 
the primary disease or because of a large inoculum of virulent bacilli. Whatever 
the source of the organism, only a few patients (less than 5%) with primary disease 
subsequently develop secondary tuberculosis. 
 
Secondary pulmonary tuberculosis is classically localized to the apex of one 
or both upper lobes. The reason is obscure but may relate to high oxygen tension in 
the apices. Because of the pre-existence of hypersensitivity, the bacilli excite a 
prompt and marked tissue response that tends to wall off the focus. As a result of 
this localization, the regional lymph nodes are less prominently involved early in 
the disease than they are in primary tuberculosis. on the other hand, cavitation 
occurs readily in the secondary form, leading to erosion into and dissemination 
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along airways. Such changes become an important source of infectivity, because 
the patient now produces sputum containing bacilli. Secondary tuberculosis should 
always be an important consideration in HIV-positive patients who present with 
pulmonary disease of note, although an increased risk of tuberculosis exists at all 
stages of HIV disease, the manifestations differ depending on the degree of 
immunosuppression. For example, patients with less severe immunosuppression 
(CD4+ counts greater than 3oo cells/mm3) present with “usual” secondary 
tuberculosis (apical disease with cavitation) while those with more advanced 
immunosuppression (CD4+ counts below 2oo cells/mm3) present with a clinical 
picture that resembles progressive primary tuberculosis (lower and middle lobe 
consolidation, hilar lymphadenopathy, and noncavitary disease). The extent of 
immunosuppression also determines the frequency of extrapulmonary 
involvement, rising from 1o% to 15% in mildly immunosuppressed patients to 
greater than 5o% in those with severe immune deficiency. 
 
MORPHOLOGY 
The initial lesion usually is a small focus of consolidation, less than 2 cm in 
diameter, within 1 to 2 cm of the apical pleura. Such foci are sharply 
circumscribed, firm, gray-white to yellow areas that have a variable amount of 
central caseation and peripheral fibrosis. In favorable cases, the initial 
parenchymal focus undergoes progressive fibrous encapsulation, leaving only 
fibrocalcific scars. Histologically, the active lesions show characteristic coalescent 
tubercles with central caseation. Although tubercle bacilli can be demonstrated by 
appropriate methods in early exudative and caseous phases of granuloma 
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formation, it is usually impossible to find them in the late, fibrocalcific stages. 
Localized, apical, secondary pulmonary tuberculosis may heal with fibrosis either 
spontaneously or after therapy, or the disease may progress and extend along 
several different pathways. Progressive pulmonary tuberculosis may ensue. The 
apical lesion enlarges with expansion of the area of caseation. Erosion into a 
bronchus evacuates the caseous center, creating a ragged, irregular cavity lined by 
caseous material that is poorly walled off by fibrous tissue. Erosion of blood 
vessels results in hemoptysis. With adequate treatment, the process may be 
arrested, although healing by fibrosis often distorts the pulmonary architecture. 
Irregular cavities, now free of caseation necrosis, may remain or collapse in the 
surrounding fibrosis. If the treatment is inadequate, or if host defenses are 
impaired, the infection may spread by direct expansion, by means of dissemination 
through airways, lymphatic channels, or within the vascular system. Miliary 
pulmonary disease occurs when organisms drain through lymphatics into the 
lymphatic ducts, which empty into the venous return to the right side of the heart 
and thence into the pulmonary arteries. Individual lesions are either microscopic or 
small, visible (2mm) foci of yellow white consolidation scattered through the lung 
parenchyma (the word miliary is derived from the resemblance of these foci to 
millet seeds). With progressive pulmonary tuberculosis, the pleural cavity is 
invariably involved and serous pleural effusions, tuberculous empyema, or 
obliterative fibrous pleuritis may develop. Endobronchial, endotracheal, and 
laryngeal tuberculosis may develop when infective material is spread either 
through lymphatic channels or from expectorated infectious material. The mucosal 
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lining may be studded with minute granulomatous lesions, sometimes apparent 
only on microscopic examination. Systemic miliary tuberculosis ensues when the 
organisms disseminate through the systemic arterial system to almost every organ 
in the body. Granulomas are the same as in the lung. Miliary tuberculosis is most 
prominent in the liver, bone marrow, spleen, adrenals, meninges, kidneys, 
fallopiantubes, and epididymis. Isolated-organ tuberculosis may appear in any one 
of the organs or tissues seeded hematogenously and may be the presenting 
manifestation of tuberculosis. organs typically involved include the meninges 
(tuberculous meningitis), kidneys (renal tuberculosis), adrenals, bones 
(osteomyelitis),and fallopian tubes (salpingitis). When the vertebrae are affected, 
the condition is referred to as Pott disease. Paraspinal “cold” abscesses may track 
along the tissue planes to present as an abdominal or pelvic mass. Lymphadenitis 
is the most frequent form of extrapulmonary tuberculosis, usually occurring in the 
cervical region (“scrofula”). Lymphadenopathy tends to be unifocal, and most 
patients do not have concurrent extranodal disease. HIV-positive patients, on the 
other hand, almost always have multifocal disease, systemic symptoms, and either 
pulmonary or other organ involvement by active tuberculosis. In years past, 
intestinal tuberculosis contracted by the drinking of contaminated milk was fairly 
common as a primary focus of tuberculosis. In developed countries today, 
intestinal tuberculosis is more often a complication of protracted advanced 
secondary tuberculosis, secondary to the swallowing of coughed-up infective 
material. Typically, the organisms are trapped in mucosal lymphoid aggregates of 
 17 
the small and large bowel, which then undergo inflammatory enlargement with 
ulceration of the overlying mucosa, particularly in the ileum. 
Clinical features of pulmonary tuberculosis: 
 Cough 
 Weight loss/anorexia 
 Fever 
 Night sweats 
 Hemoptysis 
 Chest pain 
 Fatigue 
Risk factors: 
 Sharing air space with someone sick with TB  disease (e.g., live, work, or 
play together) 
 Crowded living conditions  
 Residency or travel in a country with a high-incidence of TB disease  
 High risk occupations including laboratory and  health care jobs.  
 Systemic effects of pulmonary tuberculosis: 
Tuberculosis involving any site may produce systemic (i.e. not organ specific) 
symptoms. The frequency of fever ranges from 37 to 8o%. Loss of appetite, weight 
loss, weakness, night sweats, and malaise are also common The most common 
haematologic manifestations are increases in the peripheral blood 
polymophonuclear  leukocyte count and anaemia. Each occurs in approximately 
1o% of patients with apparently localized tuberculosis. Hyponatremia, which may 
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occur in 11% of patients is caused by the production of an antidiuretic hormone-
like substance in affected lung tissue, Tuberculosis is associated often with other 
serious disorders including: 
 HIV infection 
 alcoholism 
 drug abuse 
 chronic renal failure 
 diabetes mellitus  
 neoplastic disease 
Extrapulmonary tuberculosis: 
 Extrapulmonary tuberculosis in HIV-infected patients. 
 Disseminated tuberculosis 
 Lymph node tuberculosis 
 Pleural tuberculosis 
 Genitourinary tuberculosis 
 Skeletal tuberculosis 
 Central nervous system tuberculosis 
 Abdominal tuberculosis 
 Pericardial tuberculosis  
Disseminated tuberculosis:  Inadequacy of host defenses in containing the 
infection. The organism proliferates and disseminates throughout the body 
“miliary” tuberculosis” A finding strongly suggestive of disseminated tuberculosis 
is the choroidal tubercle, a granuloma in the retinal choroid. 
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Lymph node tuberculosis: Tuberculous lymphadenitis usually presents as 
painless swelling of one or more lymph nodes. Common site -posterior or anterior 
cervical chain of supraclavicular fossa .Rupture of the node may result in 
formation of a sinus tract, which is slow to heal. Intrathoracic adenopathy may 
compress bronchi, causing atelectasis leading to lung infection and perhaps 
bronchiectasis being particularly common in children.  
Figure - 3 
 
Pleural tuberculosis: Early on a few organisms may gain access to the 
pleural space and, in the presence of cell-mediated immunity, cause a 
hypersensitivity response . A large number of organisms spilling into the pleural 
space, usually from rupture of a cavity or an adjacent parenchymal focus via a 
bronchopleural  fistula . 
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Genitourinary tuberculosis: Dysuria , Hematuria ,Increase in frequency of 
micturition In females menstrual irregularities, pelvic pain, infertility are common 
,In males scrotal Pain is more common. 
 
Figure - 4 
 
Skeletal tuberculosis: Pain is the most common symptom .Swelling over the 
involved joint. 
 
Cns tuberculosis: Meningitis  commonly occur, tuberculoma, cranial nerve 
involvement cause headache, decreased level of consciousness and neck stiffness. 
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Figure - 5 
 
Abdominal tuberculosis: Common site Terminal ileum and caecum 
Tuberculous peritonitis frequently presents with pain often accompanied by 
abdominal swelling ,Fever, weight loss, and anorexia are also common.Rectal 
lesions usually present as anal fissures,fistulae or perirectal abscesses. 
 
Figure - 6 
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Pericardial tuberculosis:   Cardiopulmonary symptom cough, dyspnea, 
orthopnea, ankle swelling and chest pain .Chest pain may mimic angina.  
Figure - 7 
 
COMPLICATIONS OF PULMONARY TUBERCULOSIS:                    
 HEMOPTYSIS 
 PNEUMOTHORAX 
 PLEURAL EFFUSION 
 COR PULMONALE / COPD 
 TUBERCULOUS PERICARDITIS 
 TUBERCULOMA 
 DYSPHAGIA / DYSPHONIA 
 PARAPLEGIA /  PARAPERESIS  
 GENITO URINARY TB 
 GASTROINTESTINAL  TB 
 MILIARY TUBERCULOSIS 
 OTHER COMPLICATIONS 
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HEMOPTYSIS: It may be mild, moderate or massive. It usually occurs in 
advanced disease. It may be the first symptom also. Mild hemoptysis occurs due to 
inflammation which leads to capillary breakdown – diapedesis. Mild streaks of 
blood is seen in the sputum. Massive hemoptysis implies coughing up of 1oo – 6oo 
ml of blood in 24 hours. It is due to erosion of blood vessel in tb cavity or rupture 
of dilated blood vessel – Rasmussen’s aneurysm and aspergilloma formation. It 
may lead to death .5.3% of death occurs in TB due to hemoptysis and these are 
usually due to massive hemoptysis. 
 
PLEURAL EFFUSION:  It maybe mild moderate or massive. Mild effusion is 
asymptomatic. Moderate and massive pleural effusion produces symptoms 
depending on the rate of fluid accumulation. Clinical findings include tracheal 
deviation, stony dullness, straw or hemorraghic aspirate. Fluid is exudative. 
Determination of ADA is a useful screening test. Acid fast bacilli are seen in 1o – 
25% , culture is positive in 25 – 75% cases. 
Figure - 8 
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  TUBERCULOSIS EMPYEMA: Rupture of tuberculosis lesion in pleural cavity 
leads to collection of purulent fluid in pleural cavity. Encystment is usuall 
common. Pus mainly contains polymorphs. 
Figure - 9 
 
CORPULMONALE / COPD:  Extensive lung destruction leads to scarring of the 
tissue which eventually leads to corpulmonale. 5- 7 % of cases of corpulmonale in 
India is due to PTB.  There is destruction of pulmonary vasculature, tuberculous 
end arteritis and vasoconstriction. Pulmonary hypertension develops in these cases. 
Right ventricular hypertrophy and heart failure occurs eventually.  Bronchiectasis 
and other forms of chronic obstructive pulmonary disease is common in patients 
with pulmonary TB. Bronchiectasis occurs due to compression by primary 
complex or wall damage due to tuberculous granulation tissue or post tubercular 
fibrosis. 
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PNEUMOTHORAX : Spontaneous pneumothorax occurs due to rupture of sub 
pleural tuberculous lesions like bulla. Tension pneumothorax may develop. 
Pyopneumothorax is also a possibility. Acute chest pain, tightness, marked 
respiratory distress , tachycardia and cyanosis develops.  
Figure - 10 
   
 
TUBERCULOMA:  A tuberculoma is a clinical manifestation of TB which 
combines tubercles into a fine lump which mimics tumors. Tuberculomas may 
have caseum or calcifications. Cranial nerve deficits may develop. As the 
histologic and clinical indications as well as tumor markers such as CA-125 are 
similar it is often difficult to differentiate it from cancer. 
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Figure - 11 
 
DYSPHAGIA/ DYSPHONIA: This is due to complication of TB of upper 
airways. It is almost usually due to advanced cavitatory lesions in advanced PTB. 
Ulceration may be seen in laryngoscopy. 
 
TUBERCULOUS PERICARDITIS:  Tuberculous pericarditis may be sub acute; 
although acute presentation with dyspnoea, pain and friction rub is possible. An 
effusion may develop producing cardiac symptoms – cardiac tamponade. It is more 
common in elderly and HIV patients. Chronic constrictive pericarditis may 
develop due to healing of acute fibrinous or sero fibrinous pericarditis or due to 
formation of granulation tissue. Case fatality rate is high as 4o% in these 
situations. 
 
 PARAPLEGIA / PARAPERESIS: Paraplegia is a catastrophic complication of 
TB spondylitis. Neurological complications occurs early in spinal TB affecting 
upper cervical spine and ranges from single nerve palsy to paraperesis and 
quadriparesis. 
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Figure - 12 
 
 
 
GENITOURINARY TUBERCULOSIS: Patients with genito-urinary TB is 
usually asymptomatic until destructive lesions of kidneys develop in most cases. 
Severe urethral strictures leadind to hydronephrosis and renal damage may occur. 
In females TB affects fallopian tubes and endometrum leading to infertility, pelvic 
pain and menstrual abnormalities. In males TB mainly affects epidydimis 
producing a tender mass. Azoospermia or oligospermia can occur. 
 
GATRO INTESTINAL TUBERCULOSIS: Pathogenesis includes swallowing 
of sputum with direct seeding, hemotogenous spread, ingestion of milk from cows 
with bovine TB. Symptoms include abdominal pain, swelling, obstruction and 
hematochezia. Palpable mass is a common presentation. 
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Figure - 13 
 
 
 
MILIARY TUBERCULOSIS:  It is due to wide spread dissemination of  bacilli 
by hematogenous spread affecting  lungs and extrapulmonary organs such as liver, 
spleen , kidney , brain causing tiny size lesions about 1-5 mm which looks like 
millet seeds on radiograph. Hence the name , miliary TB. 
Figure - 14 
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OTHER COMPLICATIONS: TB affects eyes and causes chorioretinitis, 
panophthalmitis, uveitis and hyper sensitivity related phlyctenular conjunctivitis.  
TB of ear can cause otitis presenting as hearing loss , ottorhoea , perforation. 
Cutaneous manifestations of Tb includes abscesses ,chronic ulcers and 
scrofulderma by direct inoculation. Adrenal TB is a manifestation of disseminated 
disease presenting as adrenal insufficiency. 
 
Cardiac manifestations of pulmonary tuberculosis: 
          Pericardial involvement in tuberculosis may result in acute pericarditis, 
chronic pericardial effusion, cardiac tamponade or pericardial constriction. In 
India, TB accounts for nearly two thirds of the cases of constrictive pericarditis. 
 
The sub-acute stage of tuberculous pericarditis presents with features due to 
the presence of the pericardial fluid and those due to pericardial constriction as a 
result of the thickening of the visceral pericardium . Tuberculous pericarditis is 
always associated with a focus of tuberculosis elsewhere in the body.  
 
The disease most commonly spreads to the pericardium by direct extension 
from the tracheo bronchial tree, the mediastinal or the hilar lymph nodes, the 
sternum or the spine. The spread may also take place by a haematogenous route 
from a focus in the lung. 
 
  The tuberculous involvement of the myocardium is rare, which is seen 
mostly in association with pericardial disease. Isolated myocardial tuberculosis is 
an unusual finding; the prevalence has been reported as o.14%, o.2% and 2% in 
various series. Tuberculosis which involves the endocardium is extremely rare.  
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 The diagnosis is usually made during autopsy. Only few cases. The 
infection is a result of direct extension from the myocardium or of a 
haematogenous spread. The tuberculous involvement of the coronary vessels is 
very rare. 
 
INVESTIGATIONS: 
Mantoux Tuberculin Skin Test (TST):  
o.1 ml of tuberculin purified protein derivative (- PPD) into inner surface of 
forearm intradermally. Read between 48-72 hrs.  A positive tuberculin skin test 
result is supportive evidence in the diagnosis of TB in areas of low prevalence (or 
no vaccination); however, a negative tuberculin skin test result may occur in 
approximately one third of patients. 
 
Direct demonstration of mycobacterium by staining method:  
Sputum smear examination by microscopy: at least 1oooo bacilli per ml of 
sputum is required for positive results. Ziehl-neelsen technique is most commonly 
used.Grades according to the number of bacilli seen with ziehlneelsen staining 
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Other Staining Methods 
 Cold staining methods (kinyoun”s or with gabett”s solution) 
 Fluorescent staining using 
 Auramine-o 
 Auramine-rhodamine 
 Rhodamine 
 Acridine orange 
 
Isolation of Mycobacteria by Culture: 
Culture methods provide definitive diagnosis of mycobacterium by identity 
of the organisms and establishing the viability.The culture method is considered 
gold standard, it can detect as few as 1o to 1oo bacilli per ml. 
 
Culture characters: 
The growth appears in about two weeks but can be delayed up to six to 
eight weeks. optimum PH for growth is 6.4 to7.o. optimum temperature is 37o C. 
increased Co2 tension (5% to 1o%) enhances the growth7. 
 
Culture media: 
Solid media: 
 Lowenstein – Jensen 
 Loeffler serum slope 
 Pawlowskys potato medium 
 Tarshis medium (blood medium) 
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Liquid Media 
 Dubos medium 
 Middle brook’s medium 
 Sula’s medium 
 Sauton’s medium 
 
Colony characteristics:  
On solid media human type of tubercle bacilli give rise tofollowing 
character. It is discrete, raised, irregular, dry,wrinkled colonies. They are creamy 
white in the beginning, then develop buff colour. 
 
M.bacilli growth on solid media: 
Figure - 15 
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Rapid culture methods: 
 BACTEC radiometric system 
 Septi chek acid-fast bacilli method 
 
It is a biphasic - culture approach for detection and isolation of 
mycobacterium tuberculosis 
 
Rapid liquid tuberculosis culture also known as Mycobacteria Growth 
Indicator tube(MGIT) :  Positive signals are obtained in 1o-12 days. MGIT can 
also be used as a rapid method for the detection of drug resistant strains of Mtb 
directly from acid-fast smear positive samples as well as from indirect drug 
susceptibility  
 
Immunodiagnosis: 
 Antibody detection test:Immunoglobulin IgG and IgM detection against 
A6o antigen most commonly used. 
 
 Antigen detection test 
Lipoarabinomannan urine test 
Flow-through filter test 
 
 Polymerase chain reaction sequencing  (PCR) is based on amplification of 
mycobacterial DNA fragments. It can detect as few as 1o mycobacteria. 
Advantages of PCR include rapid diagnosis, improved specificity and 
sensitivity, and no requirement of intact immunity.This test is used for 
detection of rifampicin resistance. 
 34 
 Identification of mycobacterium by high performance liquid 
chromatography. 
 
 Gas – liquid chromatography. 
 
 GeneXpert: Xpert MTB/RIF detects M. tuberculosis as well as rifampicin 
resistance conferring mutations using three specific primers and five unique 
molecular probes to ensure a high degree of specificity. The assay provides 
results directly from the sputum within 1oo minutes, Simultaneous 
detection of both MTB and rifampicin resistance, a marker for MDR strains 
Unprecedented sensitivity for detecting MTB — even in smear negative, 
culture positive specimens, Results in two hours;  on-demand results enable 
physicians to treat rapidly and effectively. 
 
 Line probe assay:  LPA test provides an early diagnosis of resistance to 
isoniazid and rifampicin and is highly sensitive and specific for an early 
diagnosis of MDR-TB. Sensitivity for isoniazid is suboptimal • Based on 
these findings, it is concluded that the LPA test is to be implemented as first 
line test for diagnosis of drug resistant TB among sputum smear positive 
patients in high TB burden countries. 
 
 Microscopic –observation drug-susceptibility assay  The microscopic-
observation drug-susceptibility (MoDS) assay is a low-cost alternate to the 
detection of drug resistance.  MoDS detection of MDRTB was excellent 
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with sensitivity and specificity of 95 and 1oo%, respectively . The time to 
detection has been shown to be 7 days and similar to the MGIT. 
 
 Interferon-gamma release assays (IGRAs) are diagnostic tools for latent 
tuberculosis infection . They are surrogate markers of Mycobacterium 
tuberculosis infection and indicate a cellular immune response to M. 
tuberculosis.  
 
 IGRAs cannot distinguish between latent infection and active tuberculosis 
(TB) disease, and should not be used as a sole method for diagnosis of 
active TB. 
 
 QuantiFERoN-TB Gold Test and T-SPoT-TB Test are Commercially 
Available IGRAs Tests. 
 
TREATMENT oF PULMONARY TUBERCULOSIS: 
GROUPING OF ANTI-TB DRUGS 
Group 1: First-line oral anti-TB  agents 
Isoniazid (H); Rifampicin (R); Ethambutol (E); Pyrazinamide (Z) 
 
Group 2: Injectable anti-TB agents 
Streptomycin (S); Kanamycin(Km); Amikacin (Am); Capreomycin (Cm); 
Viomycin (Vm). 
 
Group 3: Fluoroquinolones 
Ciprofloxacin (Cfx); ofloxacin(ofx); Levofloxacin (Lvx); Moxifloxacin (Mfx); 
Gatifloxacin (Gfx). 
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Group 4: oral second-line anti-TB agents 
Ethionamide (Eto); Prothionamide (Pto); Cycloserine (Cs); Terizadone (Trd); 
paraaminosalicylicacid (PAS) 
 
Group 5: Agents with unclear efficacy (not recommended by WHo for routine use 
in MDR-TB patients) 
Clofazimine (Cfz); Linezolid (Lzd); Amoxicillin/Clavulanate(Amx/Clv); 
thioacetazone (Thz); imipenem/cilastatin (Ipm/Cln); high-dose isoniazid (high-
dose H); Clarithromycin (Clr) 
 
NEWER ANTI-TB DRUGS: 
 BEDAQUILINE 
 DELAMANID 
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Figure - 16 
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Name of Drug Daily dose (mg/Kg body wt) 
Adult Paediatrics 
Isoniazid 5 mg/kg (4 - 6 mg/kg) 
daily 
10 mg/kg (7 - 15 mg/kg) 
daily 
Rifampicin  
1o mg/kg (8 - 12 mg/kg) 
daily 
 
15 mg/kg (10 - 20 mg/kg) 
daily 
Streptomycin  
15 mg/kg (12 - 18 mg/kg) 
daily 
 
15 mg/kg (12 - 18 mg/kg) 
daily 
Ethambutol 15 mg/kg (15 - 20 mg/kg) 
daily 
20 mg/kg (15 - 25 mg/kg) 
daily 
Pyrazinamide 25 mg/kg (20 - 30 mg/kg) 
daily 
35 mg/kg (30 - 40mg/kg) 
daily 
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But there are significant changes in the drug regimen in the new guidelines 
Principle of treatment of TB has been shifted towards daily regimen with 
administration of daily fixed dose combination of first-line ATD as per appropriate 
weight ban 
For new TB cases: 
 Treatment in IP will consist of 8 weeks of INH, Rifampicin, Pyrazinamide 
and Ethambutol in daily dosages as per four weight bands categories. 
 There will be no need for extension of IP. 
 Only Pyrazinamide will be stopped in CP while the other three     drugs will 
be continued for another 16 weeks as daily dosages. 
 
For previously treated cases:IP will be of 12 weeks, where injection 
Streptomycin will be stopped after 8 weeks and the remaining four drugs in daily 
dosages as per weight band for another 4 weeks 
 No need of extension of IP 
 At the start of CP, Pyrazinamide will be stopped while rest of the drugs will be 
continued for another 2o weeks as daily dosages. 
 
TREATMENT OUTCOMES: 
1. Cured- A microbiologically confirmed TB at the beginning of the treatment 
who was smear or culture-negative at the end of complete treatment 
(Changed). 
2. Treatment success- TB patients either cured or treatment completed are 
accounted in the treatment success (New addition). 
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3. Failure- A TB patient whose biological specimen is positive by smear or 
culture at the end of the treatment (Changed). 
4. Lost to follow-up- A TB patient whose treatment was interrupted for one 
consecutive month or more (New addition). 
5. Not evaluated- A TB patient for whom no treatment outcome is assigned. 
(known as transfer out previously). 
6. Treatment regimen changed- Previously, it was called as switched over to 
MDR treatment.  
 
MDR/RR TB CASES (without additional resistance)                                             
 6 - 9 months of IP which includes Kanamycin, Levofoxacin, Ethambutol, 
Pyrazinamide, Ethionamide and Cycloserine. 
 18 months of CP which includes Levofoxacin, Ethambutol, Ethionamide 
and Cycloserine (no change) 
 
MDR/RR TB CASES 
 If INH resistance is not known or DST result shows sensitivity to INH, then 
addition of INH in the above-mentioned regimen of ATD is to be done 
(New addition). 
 All MDR TB cases would be subjected to Liquid Culture and DST at 
baseline for Kanamycin and Levofloxacin. 
 
NEW ADDITIONS TO DRTB GUIDELINES 
 If RR by CBNAAT, then add INH in the standard dose till result of 
LPA/LC and DST. 
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 For new patients diagnosed as TB and RR by CBNAAT – repeat CBNAAT 
and send the sample for liquid culture. 
 
DRUG RESISTANT TB 
 Introduction of new ATD under RNTCP - Bedaquiline (BDQ) 
 New class of drug, diaryl-quinoline 
 MoA = targets MTB-ATP synthase, which is essential for supply of energy 
to the bacterium 
 Has strong bactericidal and sterilizing activities against MTB 
 
Advantages 
1. No cross-resistance with first and second-line ATD 
2. Significant benefit in improving the time to culture conversion in MDR-TB 
patients. 
 
Basic criterion  
1. Adult aged ≥18 years having pulmonary MDR TB  
2. Non-pregnant females 
 
Management of TB patients with liver disorder 
If the serum alanine amino transferase level is more than three times normal 
before initiation of treatment, the regime should be 
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Containing two hepatotoxic drugs:  
a. INH + Rifampicin + Ethambutol for 9 months or INH + Rifampicin + 
Ethambutol + Streptomycin for 2 months followed by INH and Rifampicin 
for 7 months or 
b. Rifampicin + Ethambutol + Pyrazinamide for 6 - 9 months. 
 
Containing one hepatotoxic drug: 
a. INH + Ethambutol + Streptomycin for 2 months followed by INH + 
Ethambutol for 1o months. 
b. Containing no hepatotoxic drugs: Streptomycin + Ethambutol + FQ for 18–
24 months. 
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MATERIALS   AND   METHODS 
 
SOURCE OF STUDY:  
Data consists of standard 12 lead electrocardiograph taken by the principal 
investigator directly from the cases of sputum positive pulmonary tuberculosis 
admitted in the medical ward and TB chest medicine ward and from patients 
treated as outpatient in Coimbatore medical college hospital 
 
METHODOLOGY: 
This is a prospective study of 1oo cases of sputum positive pulmonary 
tuberculosis patients of  both gender and more than 2o years of age standard 12 
lead ECG  will be taken at the time of diagnosis less than 2 weeks of starting ATT 
and after completing the course of anti tuberculosis treatment and data will be 
analysed  and studied whether ATT influences ECG changes in pulmonary 
tuberculosis by follow up for six months in patients admitted or treated as 
outpatient in Coimbatore medical college hospital during the period from  may 
2017 to may 2018. 
 
INCLUSION CRITERIA: 
1. Acid fast bacilli positive cases. 
2. New cases with less than two weeks of ATT ensured by detailed history. 
3. Both gender and age more than 2o years. 
 
EXCLUSION CRITERIA:  
Pre-existing heart diseases, copd anemia, hypertension diabetes mellitus 
corpulmonale and pulmonary hypertension due to other causes 
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RESULTS 
 
TABLE - 1  
SEX DISTRIBUTION 
 
SEX NO OF PATIENTS PERCENTAGE 
MALE 78 78% 
FEMALE 22 22% 
 
 
CHART – 1 
SEX DISTRIBUTION 
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TABLE - 2  
AGE WISE DISTRIBUTION 
 
AGE IN YEARS NO OF PATIENTS PERCENTAGE 
<30 22 22% 
31-40 25 25% 
41-50 22 22% 
> 50 31 31% 
 
CHART - 2  
AGE WISE DISTRIBUTION 
 
 
 
22% 
25% 
22% 
31% 
<30 
31-40 
41-50 
> 50 
 46 
TABLE - 3 
DURATI0N 0F SYMPTOMS 
 
DURATION OF SYMPTOMS NO OF PATIENTS PERCENTAGE 
LESS THAN 6 MONTHS 59 59% 
M0RE THAN 6 MONTHS 41 41% 
 
CHART - 3  
DURATION OF SYMPTOMS 
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TABLE – 4 
ECG CHANGES - DURATION 
 
ECG CHANGES - BEFORE ATT 
DURATION OF SYMPTOMS 
MEAN SD 
PRESENT 3.51 0.52 
ABSENT 2.32 0.41 
UNPAIRED T TEST 
P VALUE - 0.012 
SIGNIFICANT 
 
CHART - 4  
DURATION OF SYMPTOMS VS ECG CHANGES 
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TABLE – 5 
 ECG CHANGES - BEFORE ATT 
 
ECG CHANGES - BEF0RE ATT NO OF PATIENTS PERCENTAGE 
PRESENT 66 66% 
ABSENT 34 34% 
 
CHART – 5  
ECG CHANGES - BEFORE ATT 
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TABLE - 6  
ECG CHANGES - AFTER ATT 
 
ECG CHANGES - AFTER ATT NO OF PATIENTS PERCENTAGE 
PRESENT 32 32% 
ABSENT 68 68% 
 
CHART - 6  
ECG CHANGES - AFTER ATT 
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TABLE -7  
ECG CHANGES – BEFORE AND AFTER ATT 
 
ECG CHANGES BEFORE AFTER 
PRESENT 64 32 
ABSENT 36 68 
 
CHART - 7  
ECG CHANGES – BEFORE AND AFTER ATT 
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TABLE - 8 
P WAVE DURATION 
 
P WAVE DURATI0N BEF0RE AFTER 
N0RMAL 100 100 
ABN0RMAL 0 0 
 
CHART - 8 
P WAVE DURATION 
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TABLE  - 9 
P WAVE AXIS 
 
P WAVE AXIS BEF0RE AFTER 
N+ 90 DEGREE 11 7 
N0RMAL 89 93 
P VALUE - 0.322 
N0N SIGNIFICANT 
 
CHART - 9 
P WAVE AXIS 
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TABLE – 10 
PR INTERVAL 
 
PR INTERVAL BEFORE AFTER 
PR0L0NGED 3 3 
N0RMAL 97 97 
P VALUE - 0.100 
N0N SIGNIFICANT 
 
TABLE – 10 
PR INTERVAL 
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TABLE – 11 
MEAN P WAVE AMPLITUDE 
 
P WAVE AMPLITUDE MEAN SD 
BEF0RE 2.17 0.66 
AFTER 1.98 0.57 
P VALUE - 0.014 
SIGNIFICANT 
 
CHART – 11 
MEAN P WAVE AMPLITUDE 
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TABLE – 12 
QRS DURATION 
 
QRS DURATION BEFORE AFTER 
N0RMAL 100 100 
ABN0RMAL 0 0 
 
CHART – 12 
QRS DURATION 
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TABLE – 13 
QRS AXIS 
 
QRS AXIS BEFORE AFTER 
N+90 DEGREES 11 5 
NORMAL 89 95 
P VALUE - 0.117 
NON SIGNIFICANT 
 
CHART – 13 
QRS AXIS 
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TABLE – 14 
QRS AMPLITUDE 
 
QRS AMPLITUDE BEFORE AFTER 
LOW 15 7 
NORMAL 85 93 
P VALUE - 0.070 
NON SIGNIFICANT 
 
CHART – 14 
QRS AMPLITUDE 
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TABLE – 15 
QT INTERVAL 
 
QT INTERVAL BEFORE AFTER 
NORMAL 100 100 
ABNORMAL 0 0 
 
CHART – 15 
QT INTERVAL 
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TABLE – 16 
ST SEGMENT 
 
ST SEGMENT BEFORE AFTER 
N0RMAL 100 100 
ABN0RMAL 0 0 
 
CHART – 16 
ST SEGMENT 
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TABLE – 17 
T WAVE 
 
T WAVE BEFORE AFTER 
INVERTED 5 1 
NORMAL 95 99 
P VALUE - 0.097 
NON SIGNIFICANT 
 
CHART – 17 
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TABLE – 18 
HEART RATE 
 
HEART RATE BEFORE AFTER 
BRADYCARDIA 2 1 
TACHYCARDIA 45 13 
P VALUE - 0.041 
SIGNIFICANT 
 
CHART – 18 
HEART RATE 
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ECG - 1 
 
Above ECG showing” low voltage complexes and sinus tachycardia” before anti 
tuberculous therapy. 
ECG - 2 
 
This ECG shows normal sinus rhythm and normal voltage after anti tuberculous 
therapy  
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ECG - 3 
 
Above ECG showing” p pulmonale and low voltage complexes” 
ECG - 4 
 
Above ECG showing” sinus arrhythmia”  
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TABLE – 19 
RHYTHM 
 
 
CHART – 19 
RHYTHM 
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TABLE – 20 
VARIOUS RHYTHM CHANGES 
 
RHYTHM NO OF PATIENTS PERCENTAGE 
APC 3 30% 
PVC 1 10% 
SINUS ARRYTHMIA 6 60% 
 
CHART – 20 
VARI0US RHYTHM CHANGES 
 
 
 
 
 
30% 
10% 
60% 
APC 
PVC 
SINUS ARRYTHMIA 
 66 
TABLE – 21 
AXIS DEVIATION 
 
AXIS DEVIATION BEFORE AFTER 
RIGHT 11 5 
NORMAL 89 95 
P VALUE - 0.117 
NON SIGNIFICANT 
                     
 CHART – 21 
AXIS DEVIATION 
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TABLE – 22 
CONDUCTION BLOCK 
 
CONDUCTION BLOCK NO OF PATIENTS PERCENTAGE 
RBBB 4 4% 
NORMAL 96 96% 
 
CHART – 22 
CONDUCTION BLOCK 
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TABLE – 23 
TEMPERATURE 
 
TEMPERATURE NO OF PATIENTS PERCENTAGE 
> 100 DEGREES 64 64% 
< 100 DEGREES 36 36% 
 
CHART – 23 
TEMPERATURE 
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TABLE – 24 
MEAN SP02 &HR WITH TEMPERATURE 
 
BEFORE ATT MEAN 
TEMPERATURE SP02 HR 
> 100 DEGREES 94.9 104.28 
< 100 DEGREES 96.27 86 
UNPAIRED T TEST 
P VALUE 0.121 0.001 
 
CHART – 24 
MEAN SP02 & HR WITH TEMPERATURE 
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TABLE – 25 
POTASSIUM VS ECG CHAGES 
 
MEAN POTASSIUM 
ECG CHANGES BEFORE AFTER 
PRESENT 4.01 4.02 
ABSENT 3.9 3.94 
 
CHART – 25 
POTASSIUM VS ECG CHAGES 
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TABLE – 26 
CALCIUM VS ECG CHAGES 
 
MEAN CALCIUM 
ECG CHANGES BEFORE AFTER 
PRESENT 9.5 9.47 
ABSENT 9.62 9.56 
 
CHART – 26 
CALCIUM VS ECG CHAGES 
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TABLE – 27 
HAEMOGLOBIN LEVELS 
 
ATT 
HAEMOGLOBIN 
MEAN SD 
BEFORE 11.53 1.29 
AFTER 11.32 1.41 
UNPAIRED T TEST 
P VALUE - 0.293 
NON SIGNIFICANT 
 
CHART – 27 
HAEMOGLOBIN LEVELS 
 
 
 
1
1
.5
3
 
1
1
.3
2
 
B E F O R E  A F T E R  
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TABLE – 28 
MEAN HEART RATE 
 
ATT 
HEART RATE 
MEAN SD 
BEF0RE 98.05 15.49 
AFTER 84.11 11.33 
UNPAIRED T TEST 
P VALUE - 0.001 
SIGNIFICANT 
 
CHART – 28 
MEAN HEART RATE 
 
 
 
 
98.05 
84.11 
BEFORE AFTER 
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TABLE – 29 
MEAN SP02 LEVELS 
 
ATT 
SP02 
MEAN SD 
BEFORE 95.4 1.48 
AFTER 97.24 0.91 
UNPAIRED T TEST 
P VALUE - 0.001 
SIGNIFICANT 
 
CHART – 29 
MEAN SP02 LEVELS 
 
 
                                                
9
5
.4
 
9
7
.2
4
 
B E F O R E  A F T E R  
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TABLE – 30 
MEAN SERUM POTASSIUM 
 
ATT 
SERUM POTASSIUM 
MEAN SD 
BEFORE 3.98 0.25 
AFTER 3.97 0.26 
UNPAIRED T TEST 
P VALUE - 0.568 
NON SIGNIFICANT 
 
CHART – 30 
MEAN SERUM POTASSIUM 
 
 
                                                
 
3
.9
8
 
3
.9
7
 
B E F O R E  A F T E R  
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TABLE – 31 
MEAN SERUM CALCIUM 
 
ATT 
SERUM CALCIUM 
MEAN SD 
BEFORE 9.54 0.51 
AFTER 9.53 0.43 
UNPAIRED T TEST 
P VALUE - 0.067 
NON SIGNIFICANT 
 
CHART – 31 
MEAN SERUM CALCIUM 
 
 
                                                
9.54 
9.53 
9.524 
9.526 
9.528 
9.53 
9.532 
9.534 
9.536 
9.538 
9.54 
9.542 
BEFORE AFTER 
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TABLE – 32 
TEMPERATURE 
 
ATT 
TEMPERATURE 
MEAN SD 
BEF0RE 100.24 0.55 
AFTER 98.57 0.33 
UNPAIRED T TEST 
P VALUE - 0.001 
SIGNIFICANT 
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DISCUSSION 
 
  In our study 100 cases of new sputum positive pulmonary tuberculosis 
without any known heart disease were studied the ECG changes before and after 
anti tuberculous therapy was observed where ECG changes seen   in 66 (66%)  
patients out of 100 and absent 34 patients, study conducted by DASTI MA et al 
showed ECG changes in 72 (72%) out of 100 in study conducted by S.N GAUR et 
al studied in 110 patents were 51 (46.4.%) showed ECG abnormalities. IN DASTI 
ET AL 67% were male and 33% were female. in our study 78% were male and 
female were 22%. In both of our studies male gender was predominant. Duration 
of symptoms in S.N GAUR ET AL was between 1 to 5 months. In our study 
duration less than 6 months was 59%  and between 6 to 12 months was 41% mean 
duration of symptoms in patients  with ECG changes 3.51 ± 0.52 ( P Value 0.012) 
which was statistically significant common ECG findings identified are sinus 
tachycardia in 45% of patients with mean 98.05 ± 15.49 before ATT and mean 
84.11 ±11.33 (p value 0.001) which is statistically significant compared to dasti 
ma et al was 22% and in S.N.Gaur  et al study  was  72%. P pulmonale was seen 5 
% with mean 2.17 ± 0.66 before ATT and mean of 1.98±0.57 AFTER ATT                   
(P Value 0.14) which was statistically significant compared to GAUR ET AL  7 
patients had p pulmonale and  in study by DASTI MA ET 9 (12.5%)  patients had 
p pulmonale in our study 15 % had low voltage complexes before ATT and 8 
patients AFTER ATT (p value 0.091) which was not statistically significant in our 
study p wave axis +9oº seen in 11 patients before ATT and in 4 patients after ATT 
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which was not statistically significant with p value o.602. in GAUR ET AL 14 
patients had p wave axis + 90º before ATT and in 5 patents after ATT.  
 
Sl. 
No. 
ECG Changes 
No. of 
abnormalities  
before ATT 
(n = 100) 
No. of 
Abnormalities 
return to normal 
after ATT (n = 100) 
Percentage of 
reversion 
after ATT 
1 Sinus tachycardia 45 32 71% 
2 Sinus bradycardia 2 1 50% 
3 P pulmonale 5 0 0% 
4 Low voltage 
complex 
15 8 53% 
5 P wave axis +90º 11 4 36.3% 
6 Qrs axis + 90º 11 6 54.5% 
7 Prolonged PR 
interval 
2 0 0% 
8 T inversion 5 4 80% 
9 Sinus arrythmia 10 4 40% 
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Sl. 
No. 
ECG Changes 
No. of 
Abnormalities  
in current 
study 
No. of 
abnormalities in 
DASTI MA et al 
No. of 
abnormalities 
in GAUR et al 
1 Sinus tachycardia 45 22 47 
2 Sinus bradycardia 02 03 01 
3 P pulmonale 05 09 07 
4 Low voltage 
complex 
15 04 20 
5 P wave axis +90º 11 - 14 
6 Qrs axis + 90º 11 05 10 
7 Prolonged PR 
interval 
02 07 - 
8 T inversion 05 - 06 
9 Sinus arrythmia 10 - 12 
 
In current study ECG changes seen are sinus tachycardia (45%), low 
voltage complex (15%), p wave axis +90º (11%), Qrs axis+90º (11%), sinus 
arrhythmia (10%), p pulmonale (5%), pr prolongation (2%), t wave inversion (5%) 
where sinus tachycardia (71%), low voltage complexes (53%), t wave inversion 
(80%) reverted to normal after anti-tuberculous therapy. 
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CONCLUSION 
 
Pulmonary tuberculosis is one of the common diseases in clinical practice 
which affects any system and cardiac involvement is one of  its complications  ,it 
can affect any cardiac region but mainly affects pericardium and less frequently 
myocardium and endocardium. In our present study sinus tachycardia, low  voltage 
complexes, Qrs axis+9oº, p pulmonale ,sinus arrhythmia are the findings    
observed  and sinus tachycardia, low voltage complexes, t wave inversion reverted 
to normal after anti-tuberculous therapy, therefore we should be aware in patients 
presenting with patients presenting with abnormal features like chest pain and  
breathlessness and with abnormal ecg findings ,where such individuals should be 
further evaluated with echocardiography and  ensure completing ATT since there 
is reversal of ECG changes after completing ATT, hence earlier development of 
irreversible cardiac complications can be prevented. 
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ANNEXURE - II 
PROFORMA 
Name  : 
Age  : 
Sex  : 
OP No : 
Department : 
Hospital : 
Address : 
Contact No : 
Occupation : 
Chief complaints 
H/O Cough with expectoration 
H/O Fever 
H/O LOW/LOA 
H/O Breathing difficulty 
H/O Fatigue 
H/O Weight loss inspite of good apptite. 
Examination 
General Examination: 
Built and nourishment, pallor, icteric, cyanosis, clubbing, lymphadenopathy, pedal 
edema. 
Systemic Examination: CVS, ABDOMEN, CNS. 
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Examination of Respiratory system: Inspection, Palpation, Percussion, 
Auscultation. 
Vitals : blood pressure, pulse rate, spo2 
Investigations 
ELECTROCARDIOGRAPHY- during presentation and follow up ECG after 6 
months 
CXR-PA View 
Sputum AFB 
Others: 
Complete Hemogram, 
Renal Function Test, 
Serum electrolytes, 
Liver Function Test, 
Blood Sugar, 
Lipid Profile. 
Treatment 
CAT-1 ATT Treatment 
Follow up ECG at end of 6 months 
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ANNEXURE - III 
CONSENT FORM 
STUDY TITLE “PROSPECTIVE STUDY ON 
ELECTROCARDIOGRAPHIC CHANGES IN SPUTUM POSITIVE 
PULMONARY TUBERCULOSIS BEFORE AND AFTER 
ANTITUBERCULOUS THERAPY” 
I…………………………………………, hereby give consent to participate in the 
study conducted by Dr.J.BALASUBRAMANIYAM, Post graduate in general 
medicine, Coimbatore  Medical College, Coimbatore  and to use my personal 
clinical data and the result of investigations for the purpose of analysis and to 
study the nature of the disease, I also give consent to give my sample for further 
investigations. I also learn that there is no additional risk in this study. I also give 
my consent for my investigator to publish the data in any forum or journal 
Signature/ Thumb impression of the patient: 
 
Patient Name & Address:                                         Signature of the investigator:     
                                                                                           
Place: 
Date:                                                                           Signature of the guide: 
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ANNEXURE - IV 
ஒப்புதல் படிவம் 
பெயர் : 
வயது : 
ொலினம் : 
முகவரி: 
 
ககாவவ அரசு மருத்துவக்கல்லூரி மருத்துவமவனயில் 
மருத்துவர்  $. ghyRg;gpukzpak; தவலவமயில் நவைபெறும் 
இந்த ஆய்வில் முழு சம்மதத்துைன் கலந்துபகாள்ள 
சம்மதிக்கிகேன். இந்த ஆய்வில் என்வன ெற்ேி விவரங்கவள 
ொதுகாப்புைன் இந்த ஆய்வில்  பவளியிை ஆட்கசெவை 
இல்வல என்று பதரிவித்துக் பகாள்கிகேன். எந்த கநரத்திலும் 
ஆய்வில் இருந்து எந்த கநரத்திலும் விலக்கிக்பகாள்ளும்  
உரிவம உண்டு என்று அேிகவன். 
 
இைம் : 
கததி: 
 
                                                              வகபகயாப்ெம்  / கரவக 
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ANNEXURE - V 
KEY TO MASTER CHART 
 
NSR  - Normal Sinus Rhythm 
A  - After ATT 
B  - Before ATT 
PVC  -  Premature Ventricular Contraction 
APC  - Atrial Premature Contraction 
RBBB  - Right Bundle Branch Block 
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ANNEXURE - VI 
MASTER CHART 
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 94 
  
 95 
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B N N 2 N N N N N N N 115  NSR N 10.4 110/70 4 9 101.7 95 -
A N N 1 N N N N N N N 90 NSR N 10.2 100/60 3.7 8.9 98.6 97 -
B N N 2.5 N N N N N N INVERTED 120 NSR N 10           110/70 3.6 10 101 94 -
A N N 2 N N N N N N INVERTED 108 NSR N 10.1 110/60 4.1 9.7 99 96 -
B N (+)90 3 N N (+)90 LOW N N N 110 NSR RIGHT 10.2 120/70 3.8 9.8 100.6 93 -
A N (+)90 3 N N N N N N N 87 NSR N 9.7 110/70 3.7 9.5 99.2 94 -
B N (+)90 2 N N (+)90 N N N N 90 NSR RIGHT 11.6 100/80 3.9 10.2 99.7 93 -
A N N 1 N N N N N N N 75 NSR N 11.5 110/80 4 9.8 98.6 97 -
B N N 2 N N N N N N N 85 NSR N 12 130/80 3.8 9.9 99.9 96 -
A N N 2.5 N N N N N N N 80 NSR N 12.2 90/60 3.6 10.2 98.5 98 -
B N N 2.5 N N N N N N N 90 NSR N 13            120/80 3.6 9.7 99.8 97 -
A N N 2 N N N N N N N 78 NSR N 12.6 130/80 3.7 9.8 98.4 98 -
B N N 2.5 N N N N N N N 87 NSR RIGHT 11.7 110/70 4 9.5 100.2 94 -
A N N 2.5 N N N N N N N 89 NSR N 10.5 100/60 4.2 9.6 98.7 96 -
B N N 2.5 N N N N N N N 88 NSR N 10.4 115/60 3.7 9.9 100.1 97 -
A N N 2 N N N N N N N 80 NSR N 10.6 125/70 4 9.3 98.6 97 -
B N N 2 N N N LOW N N N 80 NSR N 11 100/65 3.6 8.8 99.8 96 -
A N N 2 N N N LOW N N N 75 NSR N 10.8 110/75 4 8.9 98.5 98 -
B N N 1 N N N N N N N 85 NSR N 10.9 120/75 4 8.5 100 97 -
A N N 2 N N N N N N N 70 NSR N 10.8 110/80 4.2 8.9 98.1 98 -
B N N 1 N N N N N N N 86 NSR N 11.5 110/70 3.6 10.1 99.5 97 -
A N N 2.5 N N N N N N N 78 NSR N 10.9 100/60 3.7 9.8 98.5 97 -
B N N 2 N N N N N N N 80 NSR N 13           110/70 3.8 10.5 99.9 96 -
A N N 1.5 N N N N N N N 75 NSR N 13 110/60 4.1 9.7 98.4 98 -
B N N 2 N N N N N N N 120 NSR N 10 120/70 4 9.8 100.4 93 -
A N N 2 N N N N N N N 88 NSR N 10.2 110/70 4.2 9.5 99 97 -
B N N 1  PROLONGED N N N N N N 90 NSR N 11.7 100/80 3.6 8.9 100.1 96 -
A N N 2 PROLONGED N N N N N N 80 NSR N 11.4 110/80 4 8.8 98.4 98 -
B N N 2.5 N N N N N N INVERTED 115 NSR N 13 130/80 4 9.8 100.4 94 -
A N N 2.5 N N N N N N N 89 NSR N 13.3 90/60 4 9.7 98.8 97 -
B N N 3 N N N LOW N N N 116 NSR N 10.7            120/80 4.1 9.9 100.6 95 -
A N N 3 N N N LOW N N N 110 NSR N 10.5 130/80 4.3 9.8 99 95 -
B N N 2 N N N N N N N 92 (PVC) N 12 110/70 4.1 10.5 100.2 97 -
A N N 2.5 N N N N N N N 80 (PVC) N 12.7 100/60 3.6 10 98.5 97 -
B N N 2 N N N LOW N N N 85 NSR N 11.7 115/60 3.8 9.6 99 95 RBBB
A N N 2 N N N LOW N N N 78 NSR N 12 125/70 4 9.5 98.4 97 RBBB
B N N 2.5 N N N N N N N 110 NSR N 10.1 100/65 4.1 8.6 100.4 95 -
A N N 1 N N N N N N N 81 NSR N 10 110/75 3.8 8.7 98.7 97 -
B N N 2 N N N N N N N 117 SINUS ARRYTHMIA N 10 120/75 3.4 8.8 101 93 -
A N N 1 N N N N N N N 88 NSR N 10.2 110/80 3.6 8.9 99.2 96 -
B N (+)90 2.5 N N (+)90 N N N N 90 NSR RIGHT 11.2 110/70 3.9 9.7 100.1 97 RBBB
A N (+)90 2 N N (+)90 N N N N 80 NSR RIGHT 11.4 100/60 4.1 9.5 98.6 97 RBBB
B N N 1.5 N N N LOW N N N 88 NSR N 12.4           110/70 4 9 100 96 -
A N N 2 N N N LOW N N N 75 NSR N 12 110/60 4.2 9.2 98.8 98 -
B N N 3 N N N N N N N 110 NSR N 10.3 120/70 3.9 9.3 101.1 95 -
A N N 3 N N N N N N N 86 NSR N 10 110/70 4 9.5 99 97 -
B N N 2 N N (+)90 LOW N N N 106 NSR RIGHT 10.4 100/80 4.2 9.7 100.1 94 -
A N N 2 N N N N N N N 84 NSR N 10 110/80 4.4 9.5 98.2 97 -
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B N N 2.5 N N N N N N N 80 NSR N 13.2 130/80 3.6 10 99 96 -
A N N 2 N N N N N N N 75 NSR N 10.5 90/60 3.9 9.3 98.4 98 -
B N N 3 N N N N N N INVERTED 117 NSR N 10.4            120/80 4 9.8 100.3 93 -
A N N 3 N N N N N N N 86 NSR N 11.5 130/80 4.3 9.6 98.6 96 -
B N N 2.5 N N N N N N N 86 NSR N 11.9 110/70 3.6 9.5 100.1 96 -
A N N 2 N N N N N N N 75 NSR N 12 100/60 3.9 9.3 99 98 -
B N (+)90 3.5 N N (+)90 N N N N 109 NSR RIGHT 11.1 115/60 4 9.2 100.4 93 RBBB
A N (+)90 3.5 N N (+)90 N N N N 86 NSR RIGHT 10 125/70 4.1 9.7 98.2 97 RBBB
B N N 1 N N N N N N N 90 (APC) N 10.4 100/65 4.2 9.9 100.4 96 -
A N N 2 N N N N N N N 75 NSR N 10.3 110/75 4.5 9.1 98.5 98 -
B N 90 1 N N N LOW N N N 112 NSR N 10.5 120/75 4.2 10.2 100.3 96 -
A N N 2.5 N N N LOW N N N 87 NSR N 13.4 110/80 4.2 9.5 99 96 -
B N N 2 N N N N N N N 88 NSR N 14 110/70 3.8 8.7 100.2 96 -
A N N 1.5 N N N N N N N 79 NSR N 14.5 100/60 3.7 8.9 98.5 98 -
B N N 2 N N N N N N N 118 NSR N 14.1           110/70 4 9.1 100.6 95 -
A N N 2 N N N N N N N 88 NSR N 12 110/60 4.2 9.8 98.4 95 -
B N N 1 N N N N N N N 90 NSR N 12.6 120/70 3.9 10.4 99 96 -
A N N 2 N N N N N N N 78 NSR N 10.3 110/70 4 10.6 98.2 98 -
B N (+)90 2.5 N N N N N N N 116 NSR N 10.2 100/80 4.2 9 100 94 -
A N (+)90 2.5 N N N N N N N 108 NSR N 10 110/80 3.6 9.3 98.6 96 -
B N N 2 N N N N N N N 110 NSR N 10.2 130/80 3.8 9.7 101 95 -
A N N 2 N N N N N N N 83 NSR N 14 90/60 3.7 9.4 99 97 -
B N N 2 N N N N N N N 85 NSR N 14.2            120/80 4 9.8 99.8 96 -
A N N 2.5 N N N N N N N 75 NSR N 9.7 130/80 4.2 9.5 97.9 98 -
B N (+)90 2 N N N N N N N 112 NSR N 10.2 110/70 3.8 9 100.6 94 -
A N N 2 N N N N N N N 88 NSR N 12 100/60 3.7 9.3 98.7 96 -
B N N 2.5 N N N N N N N 86 NSR N 11.2 115/60 3.9 9.6 100 97 -
A N N 1 N N N N N N N 78 NSR N 10.1 125/70 4 9.8 98.6 98 -
B N N 2 N N (+)90 LOW N N N 121 NSR RIGHT 10 100/65 4.2 9.9 100.6 94 RBBB
A N N 1 N N (+)90 LOW N N N 109 NSR RIGHT 13 110/75 4.4 9.7 99.1 98 RBBB
B N N 2.5 N N N N N N N 90 SINUS ARRYTHMIA N 13.4 120/75 3.9 8.9 99.8 97 -
A N N 2 N N N N N N N 85 SINUS ARRYTHMIA N 12.4 110/70 4.1 8.8 98.1 97 -
B N N 1.5 N N N N N N N 53 NSR N 12.7 100/60 4.3 8.3 99 96 -
A N N 2 N N N N N N N 55 NSR N 10           110/70 3.8 9.4 98.6 96 -
B N N 2 N N N N N N N 111 NSR N 10.4 110/60 3.6 9.3 100.6 92 -
A N N 1 N N N N N N N 84 NSR N 13 120/70 3.9 9.7 99.1 95 -
B N N 2 N N N LOW N N N 88 NSR N 10.6 110/70 4.1 9.2 100 97 -
A N N 2.5 N N N N N N N 75 NSR N 12.6 100/80 4.3 9.8 98.1 99 -
B N N 2.5 N N N N N N N 90 NSR N 13 110/80 4 9.9 100.4 97 -
A N N 2 N N N N N N N 80 NSR N 14 130/80 4.1 9.3 98.7 97 -
B N N 3  PROLONGED N N N N N N 85 NSR N 13.1 90/60 4 8.9 99.7 97 -
A N N 3  PROLONGED N N N N N N 78 NSR N 13.8            120/80 3.8 8.8 98.4 98 -
B N N 2.5 N N N N N N N 90 NSR N 13 130/80 3.7 10.3 100.4 96 -
A N N 2 N N N N N N N 85 NSR N 10.2 110/70 3.6 10 99.8 98 -
B N (+)90 2 N N (+)90 N N N N 85 NSR RIGHT 10.6 100/60 3.9 9.9 100.3 94 -
A N (+)90 1.5 N N (+)90 N N N N 75 NSR RIGHT 10.5 115/60 4 9.8 98 98 -
B N N 1 N N N N N N N 111 SINUS ARRYTHMIA N 10.2 125/70 4.3 9.7 100.4 93 -
A N N 2 N N N N N N N 85 NSR N 11.6 100/65 3.6 9.7 98.6 96 -
B N N 1 N N N N N N N 80 NSR N 11 110/75 3.8 9.6 100.4 97 -
A N N 2.5 N N N N N N N 75 NSR N 10.1 120/75 4 9.5 98.2 99 -
B N N 2 N N N N N N N 117 NSR N 10.3 110/80 4.2 10.5 101 96 -
A N N 1.5 N N N N N N N 107 NSR N 11.8 110/70 3.8 10.3 98.7 96 -
B N N 2 N N N N N N N 90 NSR N 12 100/60 3.9 9.8 99 96 -
A N N 2.5 N N N N N N N 80 NSR N 10.1           110/70 3.7 9.7 98.1 98 -
B N N 1 N N N N N N N 107 NSR N 10.3 110/60 3.6 9.6 100.5 93 -
A N N 2 N N N N N N N 88 NSR N 11.9 120/70 4 9.5 99 97 -
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B N N 2.5 N N N N N N INVERTED 85 NSR N 12.7 110/70 4.2 9.4 100 97 -
A N N 2.5 N N N N N N N 80 NSR N 14 100/80 4.3 9.3 98.3 98 -
B N N 2 N N N N N N N 90 NSR N 13.6 110/80 4.1 10 100.4 97 -
A N N 2 N N N N N N N 75 NSR N 10.4 130/80 4.2 10.3 98.3 98 -
B N N 2 N N N N N N N 120 SINUS ARRYTHMIA N 10.7 90/60 4.1 9.8 101 94 -
A N N 2.5 N N N N N N N 90 SINUS ARRYTHMIA N 13            120/80 3.8 9.5 99 97 -
B N N 2 N N N N N N N 85 NSR N 12.7 130/80 3.9 9.8 100.1 97 -
A N N 2 N N N N N N N 80 NSR N 11 110/70 4 10 98.2 98 -
B N N 2.5 N N N N N N INVERTED 90 NSR N 11.7 100/60 4.1 9.5 99 97 -
A N N 1 N N N N N N N 86 NSR N 15 115/60 3.7 9.6 98.1 98 -
B N N 2 N N N N N N N 88 NSR N 14.3 125/70 3.6 9.3 99.7 96 -
A N N 1 N N N N N N N 75 NSR N 10 100/65 3.7 9.2 98.6 98 -
B N (+)90 3 N N (+)90 N N N N 117 NSR RIGHT 10.4 110/75 3.8 9.5 100.6 95 -
A N (+)90 3 N N N N N N N 88 NSR N 10.2 120/75 4 9.8 98.6 97 -
B N N 1.5 N N N N N N N 107 NSR N 10.4 110/80 4.1 9.6 100.3 94 -
A N N 2 N N N N N N N 89 NSR N 10 110/70 3.9 9.5 98.4 97 -
B N N 2 N N N N N N N 120 NSR N 10.6 100/60 3.7 9.3 100.6 95 -
A N N 1 N N N N N N N 110 NSR N 13           110/70 4 9.2 99 96 -
B N N 3.5 N N N LOW N N N 75 NSR N 13.7 110/60 4.3 9.4 100 98 -
A N N 3.5 N N N LOW N N N 70 NSR N 14 120/70 3.8 9 98.2 98 -
B N N 2.5 N N (+)90 N N N N 80 NSR RIGHT 13.7 110/70 3.9 9.4 100.2 95 -
A N N 2 N N N N N N N 70 NSR N 10.2 100/80 4 9.8 98.4 98 -
B N N 2 N N N N N N N 116 NSR N 10.7 110/80 4.4 9.7 100.5 95 -
A N N 2 N N N N N N N 89 NSR N 11 130/80 3.7 9.3 98.6 97 -
B N N 2.5 N N N N N N N 115 NSR N 10.5 90/60 3.9 10.6 101 93 -
A N N 2 N N N N N N N 106 NSR N 10.8            120/80 3.7 10.4 98.1 97 -
B N N 2 N N N N N N N 90 NSR N 11.4 130/80 4.6 10.2 99 96 -
A N N 2.5 N N N N N N N 85 NSR N 10.2 110/70 4.2 10.4 98 98 -
B N N 1 N N N N N N N 110 SINUS ARRYTHMIA N 10 100/60 4.4 9.7 100.7 95 -
A N N 2 N N N N N N N 84 NSR N 11.7 115/60 4.5 9.4 98.6 98 -
B N N 1 N N N N N N N 90 NSR N 12 125/70 4.2 9.5 99.7 96 -
A N N 2.5 N N N N N N N 75 NSR N 13 100/65 4 9.6 98.4 98 -
B N N 2 N N N N N N N 88 NSR N 13.7 110/75 4.1 9.7 100 97 -
A N N 1.5 N N N N N N N 75 NSR N 10 120/75 3.7 9.8 98.1 98 -
B N (+)90 3 N N N LOW N N N 111 NSR N 10.3 110/80 3.8 8.9 100.7 94 -
A N N 3 N N N N N N N 106 NSR N 14 110/70 4.5 8.4 98.6 97 -
B N N 1 N N N N N N N 80 NSR N 13.8 100/60 4.1 9 99.9 96 -
A N N 2 N N N N N N N 75 NSR N 10.2           110/70 3.6 9.3 97.9 98 -
B N N 2.5 N N N N N N N 112 NSR N 10.7 110/60 3.8 9.5 101 95 -
A N N 2.5 N N N N N N N 80 NSR N 10 120/70 3.9 9.6 99 97 -
B N N 2 N N N N N N N 112 NSR N 10.6 110/70 4 10 100.7 95 -
A N N 2 N N N N N N N 108 NSR N 14.7 100/80 4 10.1 98.8 97 -
B N N 2 N N N N N N N 90 NSR N 14.2 110/80 4.3 10.5 101.1 97 -
A N N 2.5 N N N N N N N 88 NSR N 10.7 130/80 3.8 9.9 99 97 -
B N N 2 N N N N N N N 120 NSR N 10.4 90/60 3.9 9.8 100.4 92 -
A N N 2 N N N N N N N 90 NSR N 11.3            120/80 4.2 9.7 98.6 96 -
B N N 2.5 N N N N N N N 85 (APC) N 12 130/80 4.1 9.6 100 96 -
A N N 1 N N N N N N N 80 (APC) N 12.4 110/70 4 9.5 98.4 98 -
B N N 2 PROLONGED N N N N N N 116 NSR N 11.6 100/60 3.8 9.3 101.2 93 -
A N N 1 PROLONGED N N N N N N 110 NSR N 11.8 115/60 3.9 9.2 98.8 97 -
B N N 2.5 N N N N N N N 85 NSR N 11 125/70 3.8 8.9 99 98 -
A N N 2 N N N N N N N 75 NSR N 11.1 100/65 3.7 8.8 98.1 99 -
B N N 1.5 N N N LOW N N N 119 NSR N 10 110/75 3.8 8.9 101 94 -
A N N 2 N N N N N N N 110 NSR N 10 120/75 4 9.2 98.7 97 -
B N N 2 N N N N N N N 116 NSR N 9.9 110/80 4.3 10 100.7 95 -
A N N 1 N N N N N N N 80 NSR N 13.4 110/70 4.5 10.3 98.8 97 -
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B N N 2 N N N N N N N 90 NSR N 12.8 100/60 4.4 9.9 100.4 98 -
A N N 2.5 N N N N N N N 85 NSR N 11.9           110/70 3.7 9.7 98.6 99 -
B N N 2.5 N N N N N N N 56 NSR N 11.4 110/60 3.8 9.6 100 97 -
A N N 2 N N N N N N N 67 NSR N 13.2 120/70 3.7 9.5 98.4 97 -
B N N 2 N N N N N N N 88 NSR N 12.8 110/70 3.8 9.3 100.3 97 -
A N N 2 N N N N N N N 76 NSR N 10.3 100/80 3.9 9.2 98.6 98 -
B N N 2.5 N N N LOW N N N 116 NSR N 10.6 110/80 4 9 101.1 93 -
A N N 2 N N N N N N N 110 NSR N 11.9 130/80 4.2 9.2 99 97 -
B N N 2 N N N LOW N N N 95 NSR N 12.4 90/60 4 9.8 99.8 96 -
A N N 2.5 N N N N N N N 85 NSR N 10.4            120/80 3.9 9.7 98.3 97 -
B N (+)90 1 N N (+)90 N N N N 109 (APC) RIGHT 10.6 130/80 4.5 9.6 100.5 94 -
A N N 2 N N N N N N N 86 (APC) N 11 110/70 4.2 9.3 98.6 97 -
B N N 1 N N N N N N N 109 NSR N 10.7 100/60 4.3 9 100.6 94 -
A N N 2.5 N N N N N N N 81 NSR N 14 115/60 4 8.8 98.7 96 -
B N N 2 N N N N N N N 85 NSR N 13.1 125/70 4.2 9.5 100.1 97 -
A N N 1.5 N N N N N N N 75 NSR N 12.1 100/65 3.6 9.8 98.6 97 -
B N N 2 N N N LOW N N N 90 NSR N 11.4 110/75 4.2 9 99.9 96 -
A N N 2 N N N N N N N 80 NSR N 10.4 120/75 3.8 9.3 98.2 98 -
B N N 1 N N N N N N N 109 NSR N 9.8 110/80 4.3 10.3 100.8 94 -
A N N 2 N N N N N N N 82 NSR N 12.6 110/70 4.5 10.4 98.9 97 -
B N N 2.5 N N N N N N N 90 NSR N 11.9 100/60 3.9 9.2 100 97 -
A N N 2.5 N N N N N N N 85 NSR N 14.1           110/70 3.8 9.8 98.1 97 -
B N N 2 N N N N N N N 85 NSR N 13.6 110/60 4.1 8.9 100.6 97 -
A N N 2 N N N N N N N 70 NSR N 10.7 100/70 4.2 9.4 98.5 98 -
B N (+)90 3.5 N N (+)90 N N N N 120 NSR RIGHT 12.3 110/70 3.8 8.6 100.7 95 -
A N (+)90 3.5 N N (+)90 N N N N 110 NSR RIGHT 11.5 100/80 4.3 10.2 99 98 -
B N N 2 N N N N N N N 112 SINUS ARRYTHMIA N 10.3 110/80 4.6 10.1 101 94 -
A N N 2 N N N N N N N 89 SINUS ARRYTHMIA N 10 130/80 4.7 10 98.6 97 -
B N N 2.5 N N N N N N N 75 NSR N 13.4 90/60 3.8 9 99.8 97 -
A N N 1 N N N N N N N 65 NSR N 12.6            120/80 3.5 8.8 98.3 97 -
B N N 2 N N N N N N N 85 NSR N 10.4 130/80 4.1 8.9 100.6 97 -
A N N 1 N N N N N N N 78 NSR N 10.2 110/70 3.9 9.1 98.7 98 -
B N N 2.5 N N N N N N N 117 NSR N 10.7 100/60 4.7 9.6 100 95 -
A N N 2 N N N N N N N 86 NSR N 12.6 115/60 4.4 9.8 98.7 98 -
B N N 1.5 N N N N N N N 90 NSR N 12 125/70 3.8 10.4 100.2 97 -
A N N 2 N N N N N N N 80 NSR N 13 100/65 4.3 10.5 98.6 97 -
B N N 2 N N N N N N N 115 NSR N 10.5 110/75 4.2 9.8 100.4 94 -
A N N 1 N N N N N N N 80 NSR N 9.9 120/75 3.8 9.9 99 97 -
B N N 2 N N N N N N N 85 NSR N 11.5 110/80 3.5 8.9 99.9 96 -
A N N 2.5 N N N N N N N 75 NSR N 10.8 110/70 3.4 9.3 98.3 97 -
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